about
Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparationsExpanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligandsChemistry and structural biology of androgen receptorMarketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant TherapyAge disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men.Transcriptional role of androgen receptor in the expression of long non-coding RNA Sox2OT in neurogenesis.Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.Spectrophotometric estimation of bicalutamide in tablets.Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzymeSafety of antiandrogen therapy for treating prostate cancer.Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening methodA phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells.Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase.Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer.A systematic review on drug interactions in oncology.Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.Occurrence and fate of selected anticancer, antimicrobial, and psychotropic pharmaceuticals in an urban river in a subcatchment of the Yodo River basin, Japan.Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamideUse of In Vitro Morphogenesis of Mouse Embryoid Bodies to Assess Developmental Toxicity of Therapeutic Drugs Contraindicated in Pregnancy.Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.Mechanistic studies on the synthesis of bicalutamide.Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein.Potential drug interactions and duplicate prescriptions among cancer patients.Selective androgen receptor modulators: comparative excretion study of bicalutamide in bovine urine and faeces.Validation of RP-HPLC Method for Simultaneous Quantification of Bicalutamide and Hesperetin in Polycaprolactone-Bicalutamide-Hesperetin-Chitosan Nanoparticles.Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.Characteristics of bicalutamide solid dispersions and improvement of the dissolution.Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.
P2860
Q24676629-B197D02D-99DE-4DDF-B8CD-82A903CC6A50Q24680340-1928ED24-9604-47FC-BBAF-BAD9B7147089Q24680373-A8EAA30B-A037-4A0F-A79B-A59168691F41Q24685498-6ED4FD9D-7AE3-4CA9-9D22-B1C83D55052BQ28263601-6D22E07A-D4C0-4A12-96A2-13EEBCD7240FQ30430407-73193C00-F6BB-48EA-B120-718CD490A255Q33898591-8CB35D7B-38FC-4392-B465-A08BB13681D1Q33918464-021CBDED-3467-413D-B65B-6CFD1FE8C786Q34168224-776D9F7C-1151-404A-8F50-4838AF0BFEB3Q34335228-2158D425-CC35-4A9E-A076-7DAD98A4C8F5Q34441134-080EEE5E-C8C2-4CDC-BCFC-CF6552931F1EQ34453023-6E0ADA6F-81C6-42EF-8699-6CE3E72E5ECAQ34520021-9D955A4B-4D10-4D61-86F5-66029566F4B1Q34534111-DEED3949-944C-4866-9399-90B592AE4D9DQ34900827-1F740045-1FFF-40EB-985F-A30DCC3FE5A7Q35166343-1310802F-B330-4DBF-A453-FBFB08BEE718Q36087736-145725A7-4997-4AD8-AB8A-51CB4B6DC0ACQ36411209-71F5AE39-55A8-4150-B7E4-38A1AAF446ADQ36659821-AE0091CD-6C4A-4A4A-83BB-7BD6FF65A51AQ37682137-08C00627-6242-4E7C-82D1-43BE8219C34CQ37685527-C610E58F-32EF-42F4-B0F2-FDA4AA0C7780Q38922287-B3768142-7410-4B08-B9C5-014AB520562BQ39405509-F91795AD-A866-4324-8BBF-A1B5F8370D91Q40296939-B3B5ECB7-84A1-459B-988F-AC8559312BD1Q42096206-04B83F43-F41E-48FC-810D-586B3D4FA30BQ42820771-822C3EB9-5E5B-4E7D-B0D6-ED874F83FC3CQ43786966-1C65A57B-B2FE-4027-9918-A28D80EBEC8CQ44533503-D2B47D42-6765-4C95-A33F-6E0618250125Q46132902-1032CFCC-BEF9-45F1-9451-066A1C1F9C27Q47610526-15AA5AFB-36C6-4323-B63D-DF648BA09945Q47695462-EC8E89EE-C73E-4523-AEB5-E479D8367ECCQ48199350-E6CA241D-EB1A-42D7-A9A1-B2BFE35A2248Q48308625-6E7030FE-CE36-4C41-8C36-3E00B0080068Q49041218-E0EFFA5A-B8A7-4BEE-8EDD-4DEA45FE84A2Q50020219-19C1B286-4766-4113-8AF8-C951E6E1914FQ51136853-52FDAB23-749F-4722-A4A7-BC8D26EA4AF1Q52677958-F4AEE2A7-0F6E-4FF3-BA24-8F517718DE22
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Bicalutamide: clinical pharmacokinetics and metabolism.
@ast
Bicalutamide: clinical pharmacokinetics and metabolism.
@en
type
label
Bicalutamide: clinical pharmacokinetics and metabolism.
@ast
Bicalutamide: clinical pharmacokinetics and metabolism.
@en
prefLabel
Bicalutamide: clinical pharmacokinetics and metabolism.
@ast
Bicalutamide: clinical pharmacokinetics and metabolism.
@en
P1476
Bicalutamide: clinical pharmacokinetics and metabolism.
@en
P2093
Ian D Cockshott
P304
P356
10.2165/00003088-200443130-00003
P577
2004-01-01T00:00:00Z
P6179
1042773399